Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “Funding”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 523 records · Page 29

Load Mitigation on Floating Offshore Wind Turbines with Advanced Controls and Tuned Mass Dampers

General Electric, the National Renewable Energy Laboratory (NREL), the University of Massachusetts Amherst (UMass), and Glosten have recently completed a US Department of Energy (DOE)-funded research program to study technologies for mitigating loads on floating offshore wind turbines through the use of advanced turbine controls and tuned mass dampers (TMDs). The analysis was based upon the Glosten PelaStar tension leg platform (TLP) with GE Haliade 150 turbine, a system developed in a previous front end engineering design (FEED) study funded by the Energy Technology Institute (ETI) in the UK. The platform was designed for the WaveHub wave energy research site, with a mean water depth of 59-m. Loads were analyzed by running time-domain simulations in four 50-year return period (50-YRP) ultimate load state (ULS) conditions and 77 fatigue load state (FLS) environmental conditions. In 50-YRP conditions advanced controls are not active. The influence of TMDs on ULS loads have been reported previously (Park et al. [2]). In FLS conditions advanced controls and TMDs afford dramatic reductions in fatigue damage, offering the potential of significant savings in tower structural requirements. Simulations in turbine idling conditions were run in OrcaFlex, and simulations in operating conditions were run in FAST. Simulations were run with a baseline turbine controller, representative of the current state of the art, and an advanced controller developed by NREL to use collective and individual blade pitch control to maintain rotor speed and reduce tower loads. UMass developed a number of TMD types, with varying system configurations, including passive nonlinear dampers and semi-actively controlled dampers with an inverse velocity groundhook control algorithm. Loads and accelerations in FLS conditions were evaluated on the basis of damage equivalent loads (DELs), and fatigue damage was computed by Miner's summations of stress cycles at the tower base. To study sensitivity to water depth, loads were analyzed at both the 59-m WaveHub depth and a more commercially realistic depth of 100 m. TMDs reduce fatigue damage at the tower-column interface flange by up to 52% in 59-m water depth and up to 28% in 100 m water depth. Advanced controls reduce fatigue damage at the tower-column flange by up to 22% in 59-m water depth and up to 40% in 100 m water depth. The most effective load-mitigation strategy is combining advanced controls with TMDs. This strategy affords a 71% reduction in fatigue damage in both 59-m and 100-m water depths.

17 WIND ENERGY↗

TH-C-18A-01: Is Automatic Tube Current Modulation Still Necessary with Statistical Iterative Reconstruction?

Purpose: Automatic tube current modulation (TCM) has been widely used in modern multi-detector CT to reduce noise spatial nonuniformity and streaks to improve dose efficiency. With the advent of statistical iterative reconstruction (SIR), it is expected that the importance of TCM may diminish, since SIR incorporates statistical weighting factors to reduce the negative influence of photon-starved rays. The purpose of this work is to address the following questions: Does SIR offer the same benefits as TCM? If yes, are there still any clinical benefits to using TCM? Methods: An anthropomorphic CIRS chest phantom was scanned using a state-of-the-art clinical CT system equipped with an SIR engine (Veo™, GE Healthcare). The phantom was first scanned with TCM using a routine protocol and a low-dose (LD) protocol. It was then scanned without TCM using the same protocols. For each acquisition, both FBP and Veo reconstructions were performed. All scans were repeated 50 times to generate an image ensemble from which noise spatial nonuniformity (NSN) and streak artifact levels were quantified. Monte-Carlo experiments were performed to estimate skin dose. Results: For FBP, noise streaks were reduced by 4% using TCM for both routine and LD scans. NSN values were actually slightly higher with TCM (0.25) than without TCM (0.24) for both routine and LD scans. In contrast, for Veo, noise streaks became negligible (<1%) with or without TCM for both routine and LD scans, and the NSN was reduced to 0.10 (low dose) or 0.08 (routine). The overall skin dose was 2% lower at the shoulders and more uniformly distributed across the skin without TCM. Conclusion: SIR without TCM offers superior reduction in noise nonuniformity and streaks relative to FBP with TCM. For some clinical applications in which skin dose may be a concern, SIR without TCM may be a better option. K. Li, W. Zhao, D. Gomez-Cardona: Nothing to disclose; G.-H. Chen: Research funded, General Electric Company Research funded, Siemens AG Research funded, Varian Medical Systems, Research funded, Hologic, Inc.

60 APPLIED LIFE SCIENCES↗

TH-E-17A-09: High Quality and Artifact-Free 4D Cone Beam CT and Its Application in Adaptive Treatment Planning

Purpose: To develop a high quality 4D cone beam CT (4DCBCT) method that is immune to patient/couch truncations and to investigate its application in adaptive replanning of lung XRT. Methods: In this study, IRB-approved human subject CBCT data was acquired using a Varian on-board imager with 1 minute rotation time. The acquired projection data was retrospectively sorted into 20 respiratory phase bins, from which 4DCBCT images with high SNR and high temporal resolution were generated using Prior Image Constrained Compressed Sensing (PICCS). Couch and patient truncations generate strong data inconsistency in the projection data and artifacts in the 4DCBCT image. They were addressed using an adaptive PICCS method. The artifact-free PICCS-4DCBCT images were used to generate adaptive treatment plans for the same patient at the 10th (day 21) and 30th (day 47) fractions. Dosimetric impacts with and without PICCS- 4DCBCT were evaluated by isodose distributions, DVHs, and other dosimetric factors. Results: The adaptive PICCS-4DCBCT method improves image quality by removing residue truncation artifacts; measured universal image quality increased 37%. The isodose lines and DVHs with PICCS-4DCBCT-based adaptive replanning were significantly more conformal to PTV than without replanning due to changes in patient anatomy caused by progress of the treatment. The mean dose to PTV at the 10th fraction was 63.1Gy with replanning and 64.2Gy without replanning, where the prescribed dose was 60Gy, in 2Gy × 30 fractions. The mean dose to PTV at the 30th fraction was 61.6Gy with replanning and 64.9Gy without replanning. Lung V20 was 37.1%, 41.9% and 43.3% for original plan, 10th fraction plan and 30th fraction plan; with re-planning, Lung V20 was 37.1%, 32%, 27.8%. Conclusion: 4DCBCT imaging using adaptive PICCS is able to generate high quality, artifact-free images that potentially can be used to create replanning for improving radiotherapy of the lung. K Niu, K Li, J Smilowitz: Nothing to Disclose. G Chen: General Electric Company Research funded, Siemens AG Research funded, Varian Medical Systems Research funded, Hologic Research funded.

60 APPLIED LIFE SCIENCES↗

MO-C-BRB-00: President’s Symposium: Revitalizing Scientific Excellence: Turning Research Into Clinical Reality Through Translational Research

Diagnostic radiology and radiation oncology are arguably two of the most technologically advanced specialties in medicine. The imaging and radiation medicine technologies in clinical use today have been continuously improved through new advances made in the commercial and academic research arenas. This symposium explores the translational path from research through clinical implementation. Dr. Pettigrew will start this discussion by sharing his perspectives as director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The NIBIB has focused on promoting research that is technological in nature and has high clinical impact. We are in the age of precision medicine, and the technological innovations and quantitative tools developed by engineers and physicists working with physicians are providing innovative tools that increase precision and improve outcomes in health care. NIBIB funded grants lead to a very high patenting rate (per grant dollar), and these patents have higher citation rates by other patents, suggesting greater clinical impact, as well. Two examples of clinical translation resulting from NIH-funded research will be presented, in radiation therapy and diagnostic imaging. Dr. Yu will describe a stereotactic radiotherapy device developed in his laboratory that is designed for treating breast cancer with the patient in the prone position. It uses 36 rotating Cobalt-60 sources positioned in an annular geometry to focus the radiation beam at the system’s isocenter. The radiation dose is delivered throughout the target volume in the breast by constantly moving the patient in a planned trajectory relative to the fixed isocenter. With this technique, the focal spot dynamically paints the dose distribution throughout the target volume in three dimensions. Dr. Jackson will conclude this symposium by describing the RSNA Quantitative Imaging Biomarkers Alliance (QIBA), which is funded in part by NIBIB and is a synergistic collaboration between medical physicists, radiologists, oncologists, industry representatives, and other stakeholders. The mission of QIBA is to improve the accuracy and practicality of quantitative image-based biomarkers by increasing precision across devices, patients, and time, an essential step in incorporating quantitative imaging biomarkers into radiology practice. Validated quantitative imaging biomarkers are necessary to support precision medicine initiatives, multimodality / multiparametric applications in medicine, treatment planning and response assessment, and radiogenomics applications. Current applications in the QIBA portfolio extend to cancer diagnosis and treatment, pulmonary diseases, and neurological disorders. The overall goal of this symposium is to illustrate the bidirectional exchange between medical research and clinical practice. Revitalizing scientific excellence in clinical medical physics challenges practitioners to identify clinical limitations, which then drive research innovation; research funded by the NIH and other agencies develops technological solutions to these limitations, which are translated to the care environment to ultimately improve clinical practice in radiology and radiation oncology.

60 APPLIED LIFE SCIENCES↗

MO-C-BRB-01: Introduction [ Diagnostic radiology and radiation oncology ]

Diagnostic radiology and radiation oncology are arguably two of the most technologically advanced specialties in medicine. The imaging and radiation medicine technologies in clinical use today have been continuously improved through new advances made in the commercial and academic research arenas. This symposium explores the translational path from research through clinical implementation. Dr. Pettigrew will start this discussion by sharing his perspectives as director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The NIBIB has focused on promoting research that is technological in nature and has high clinical impact. We are in the age of precision medicine, and the technological innovations and quantitative tools developed by engineers and physicists working with physicians are providing innovative tools that increase precision and improve outcomes in health care. NIBIB funded grants lead to a very high patenting rate (per grant dollar), and these patents have higher citation rates by other patents, suggesting greater clinical impact, as well. Two examples of clinical translation resulting from NIH-funded research will be presented, in radiation therapy and diagnostic imaging. Dr. Yu will describe a stereotactic radiotherapy device developed in his laboratory that is designed for treating breast cancer with the patient in the prone position. It uses 36 rotating Cobalt-60 sources positioned in an annular geometry to focus the radiation beam at the system’s isocenter. The radiation dose is delivered throughout the target volume in the breast by constantly moving the patient in a planned trajectory relative to the fixed isocenter. With this technique, the focal spot dynamically paints the dose distribution throughout the target volume in three dimensions. Dr. Jackson will conclude this symposium by describing the RSNA Quantitative Imaging Biomarkers Alliance (QIBA), which is funded in part by NIBIB and is a synergistic collaboration between medical physicists, radiologists, oncologists, industry representatives, and other stakeholders. The mission of QIBA is to improve the accuracy and practicality of quantitative image-based biomarkers by increasing precision across devices, patients, and time, an essential step in incorporating quantitative imaging biomarkers into radiology practice. Validated quantitative imaging biomarkers are necessary to support precision medicine initiatives, multimodality / multiparametric applications in medicine, treatment planning and response assessment, and radiogenomics applications. Current applications in the QIBA portfolio extend to cancer diagnosis and treatment, pulmonary diseases, and neurological disorders. The overall goal of this symposium is to illustrate the bidirectional exchange between medical research and clinical practice. Revitalizing scientific excellence in clinical medical physics challenges practitioners to identify clinical limitations, which then drive research innovation; research funded by the NIH and other agencies develops technological solutions to these limitations, which are translated to the care environment to ultimately improve clinical practice in radiology and radiation oncology.

60 APPLIED LIFE SCIENCES↗

MO-C-BRB-02: ASTRO President [ Diagnostic radiology and radiation oncology ]

Diagnostic radiology and radiation oncology are arguably two of the most technologically advanced specialties in medicine. The imaging and radiation medicine technologies in clinical use today have been continuously improved through new advances made in the commercial and academic research arenas. This symposium explores the translational path from research through clinical implementation. Dr. Pettigrew will start this discussion by sharing his perspectives as director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The NIBIB has focused on promoting research that is technological in nature and has high clinical impact. We are in the age of precision medicine, and the technological innovations and quantitative tools developed by engineers and physicists working with physicians are providing innovative tools that increase precision and improve outcomes in health care. NIBIB funded grants lead to a very high patenting rate (per grant dollar), and these patents have higher citation rates by other patents, suggesting greater clinical impact, as well. Two examples of clinical translation resulting from NIH-funded research will be presented, in radiation therapy and diagnostic imaging. Dr. Yu will describe a stereotactic radiotherapy device developed in his laboratory that is designed for treating breast cancer with the patient in the prone position. It uses 36 rotating Cobalt-60 sources positioned in an annular geometry to focus the radiation beam at the system’s isocenter. The radiation dose is delivered throughout the target volume in the breast by constantly moving the patient in a planned trajectory relative to the fixed isocenter. With this technique, the focal spot dynamically paints the dose distribution throughout the target volume in three dimensions. Dr. Jackson will conclude this symposium by describing the RSNA Quantitative Imaging Biomarkers Alliance (QIBA), which is funded in part by NIBIB and is a synergistic collaboration between medical physicists, radiologists, oncologists, industry representatives, and other stakeholders. The mission of QIBA is to improve the accuracy and practicality of quantitative image-based biomarkers by increasing precision across devices, patients, and time, an essential step in incorporating quantitative imaging biomarkers into radiology practice. Validated quantitative imaging biomarkers are necessary to support precision medicine initiatives, multimodality / multiparametric applications in medicine, treatment planning and response assessment, and radiogenomics applications. Current applications in the QIBA portfolio extend to cancer diagnosis and treatment, pulmonary diseases, and neurological disorders. The overall goal of this symposium is to illustrate the bidirectional exchange between medical research and clinical practice. Revitalizing scientific excellence in clinical medical physics challenges practitioners to identify clinical limitations, which then drive research innovation; research funded by the NIH and other agencies develops technological solutions to these limitations, which are translated to the care environment to ultimately improve clinical practice in radiology and radiation oncology.

60 APPLIED LIFE SCIENCES↗

MO-C-BRB-03: RSNA President [ Diagnostic radiology and radiation oncology ]

Diagnostic radiology and radiation oncology are arguably two of the most technologically advanced specialties in medicine. The imaging and radiation medicine technologies in clinical use today have been continuously improved through new advances made in the commercial and academic research arenas. This symposium explores the translational path from research through clinical implementation. Dr. Pettigrew will start this discussion by sharing his perspectives as director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB). The NIBIB has focused on promoting research that is technological in nature and has high clinical impact. We are in the age of precision medicine, and the technological innovations and quantitative tools developed by engineers and physicists working with physicians are providing innovative tools that increase precision and improve outcomes in health care. NIBIB funded grants lead to a very high patenting rate (per grant dollar), and these patents have higher citation rates by other patents, suggesting greater clinical impact, as well. Two examples of clinical translation resulting from NIH-funded research will be presented, in radiation therapy and diagnostic imaging. Dr. Yu will describe a stereotactic radiotherapy device developed in his laboratory that is designed for treating breast cancer with the patient in the prone position. It uses 36 rotating Cobalt-60 sources positioned in an annular geometry to focus the radiation beam at the system’s isocenter. The radiation dose is delivered throughout the target volume in the breast by constantly moving the patient in a planned trajectory relative to the fixed isocenter. With this technique, the focal spot dynamically paints the dose distribution throughout the target volume in three dimensions. Dr. Jackson will conclude this symposium by describing the RSNA Quantitative Imaging Biomarkers Alliance (QIBA), which is funded in part by NIBIB and is a synergistic collaboration between medical physicists, radiologists, oncologists, industry representatives, and other stakeholders. The mission of QIBA is to improve the accuracy and practicality of quantitative image-based biomarkers by increasing precision across devices, patients, and time, an essential step in incorporating quantitative imaging biomarkers into radiology practice. Validated quantitative imaging biomarkers are necessary to support precision medicine initiatives, multimodality / multiparametric applications in medicine, treatment planning and response assessment, and radiogenomics applications. Current applications in the QIBA portfolio extend to cancer diagnosis and treatment, pulmonary diseases, and neurological disorders. The overall goal of this symposium is to illustrate the bidirectional exchange between medical research and clinical practice. Revitalizing scientific excellence in clinical medical physics challenges practitioners to identify clinical limitations, which then drive research innovation; research funded by the NIH and other agencies develops technological solutions to these limitations, which are translated to the care environment to ultimately improve clinical practice in radiology and radiation oncology.

60 APPLIED LIFE SCIENCES↗

MO-FG-213-04: Managing the Relationship

Academic-industrial collaborations are playing an increasingly prominent role in medical physics research. Successful partnerships have enabled truly translational, benchtop-to-bedside research that has significantly and positively impacted our field. Given the current flat or depleting trends in federal funding, and the increasing emphasis in the medical physics community on demonstrating translatability, efficacy, and safety prior to widespread clinical use, it is anticipated that such partnerships will become ever more important in advancing our field. In the future, it is likely that neither academia alone, nor industry alone, will be able to bring significant innovation to successfully impact patient care in radiotherapy. Such innovation will require partnership and symbiosis through the lifetime of the project. This symposium is aimed at professionals from academia and the industry who are interested in either initiating new collaborations or maintaining and improving existing partnerships. We will hear from four thought leaders from industry and academia on critical aspects of building and maintaining successful academic-industrial research partnerships. The following topics will be addressed: 1. Motivations: The industry perspective [Kevin Brown, Elekta] What goes into the development of a company’s R&D roadmap What are the motivations and expectations of the industry from academic partners How can academics make a successful pitch by identifying projects aligned with a company’s roadmap Why are some relationships successful and some not Milestones and progress reports - Why do we need them 2. Motivations: The academic perspective [T. Rock Mackie, Univ. of Madison, WI; Tomotherapy] What are the motivations and expectations of academic partners from the industry What are the cultural differences in academia vs industry on sharing information, exchanging ideas Partnership or entrepreneurship? When does each option make sense 3. Industrial Grants and Research Contracts – a Primer [Norbert Pelc; Stanford University] What topics are suited to industrial grants vs. academic grants How do resources (personnel effort, tuition) get allocated and charged in academia What are reasonable resource and timeline requests for small and big projects; from small and big companies “Fair market value” considerations Sections of a research agreement (IP including software confidential information, publications, data, exclusivity, support) 4. Managing the relationship [John Wong, Johns Hopkins University] How to effectively collaborate with each other How to adapt to changes in the relationship How to renew funding with the industry Moderated Panel Discussion [All speakers + moderators] Learning Objectives: 1. Understand the motivations of each partner 2. Elements that contribute to a successful partnership 3. Avoiding pitfalls - Challenges on either side that may derail a project 4. How to frame a research grant and agreement 5. How to sustain the collaborative relationship Amit Sawant: Funding from: NIH. Varian, Elekta and VisionRT; Michelle Svatos: Employee and shareholder: Varian, Board Member, TopasMC; Kevin Brown: Employee, Elekta; T. Rock Mackie: Consultant, Accuray; Norbert Pelc: Research support: Philips Healthcare, GE Healthcare; John Wong: Funding from NIH, Xstrahl and Elekta. Co-founder and advisor for JPLC Associates, LLC.

07 ISOTOPE AND RADIATION SOURCES↗

WE-H-206-00: Advances in Preclinical Imaging

Lihong V. Wang: Photoacoustic tomography (PAT), combining non-ionizing optical and ultrasonic waves via the photoacoustic effect, provides in vivo multiscale functional, metabolic, and molecular imaging. Broad applications include imaging of the breast, brain, skin, esophagus, colon, vascular system, and lymphatic system in humans or animals. Light offers rich contrast but does not penetrate biological tissue in straight paths as x-rays do. Consequently, high-resolution pure optical imaging (e.g., confocal microscopy, two-photon microscopy, and optical coherence tomography) is limited to penetration within the optical diffusion limit (∼1 mm in the skin). Ultrasonic imaging, on the contrary, provides fine spatial resolution but suffers from both poor contrast in early-stage tumors and strong speckle artifacts. In PAT, pulsed laser light penetrates tissue and generates a small but rapid temperature rise, which induces emission of ultrasonic waves due to thermoelastic expansion. The ultrasonic waves, orders of magnitude less scattering than optical waves, are then detected to form high-resolution images of optical absorption at depths up to 7 cm, conquering the optical diffusion limit. PAT is the only modality capable of imaging across the length scales of organelles, cells, tissues, and organs (up to whole-body small animals) with consistent contrast. This rapidly growing technology promises to enable multiscale biological research and accelerate translation from microscopic laboratory discoveries to macroscopic clinical practice. PAT may also hold the key to label-free early detection of cancer by in vivo quantification of hypermetabolism, the quintessential hallmark of malignancy. Learning Objectives: To understand the contrast mechanism of PAT To understand the multiscale applications of PAT Benjamin M. W. Tsui: Multi-modality molecular imaging instrumentation and techniques have been major developments in small animal imaging that has contributed significantly to biomedical research during the past decade. The initial development was an extension of clinical PET/CT and SPECT/CT from human to small animals and combine the unique functional information obtained from PET and SPECT with anatomical information provided by the CT in registered multi-modality images. The requirements to image a mouse whose size is an order of magnitude smaller than that of a human have spurred advances in new radiation detector technologies, novel imaging system designs and special image reconstruction and processing techniques. Examples are new detector materials and designs with high intrinsic resolution, multi-pinhole (MPH) collimator design for much improved resolution and detection efficiency compared to the conventional collimator designs in SPECT, 3D high-resolution and artifact-free MPH and sparse-view image reconstruction techniques, and iterative image reconstruction methods with system response modeling for resolution recovery and image noise reduction for much improved image quality. The spatial resolution of PET and SPECT has improved from ∼6–12 mm to ∼1 mm a few years ago to sub-millimeter today. A recent commercial small animal SPECT system has achieved a resolution of ∼0.25 mm which surpasses that of a state-of-art PET system whose resolution is limited by the positron range. More recently, multimodality SA PET/MRI and SPECT/MRI systems have been developed in research laboratories. Also, multi-modality SA imaging systems that include other imaging modalities such as optical and ultrasound are being actively pursued. In this presentation, we will provide a review of the development, recent advances and future outlook of multi-modality molecular imaging of small animals. Learning Objectives: To learn about the two major multi-modality molecular imaging techniques of small animals. To learn about the spatial resolution achievable by the molecular imaging systems for small animal today. To learn about the new multi-modality imaging instrumentation and techniques that are being developed. Sang Hyun Cho; X-ray fluorescence (XRF) imaging, such as x-ray fluorescence computed tomography (XFCT), offers unique capabilities for accurate identification and quantification of metals within the imaging objects. As a result, it has emerged as a promising quantitative imaging modality in recent years, especially in conjunction with metal-based imaging probes. This talk will familiarize the audience with the basic principles of XRF/XFCT imaging. It will also cover the latest development of benchtop XFCT technology. Additionally, the use of metallic nanoparticles such as gold nanoparticles, in conjunction with benchtop XFCT, will be discussed within the context of preclinical multimodal multiplexed molecular imaging. Learning Objectives: To learn the basic principles of XRF/XFCT imaging To learn the latest advances in benchtop XFCT development for preclinical imaging Funding support received from NIH and DOD; Funding support received from GE Healthcare; Funding support received from Siemens AX; Patent royalties received from GE Healthcare; L. Wang, Funding Support: NIH; COI: Microphotoacoustics; S. Cho, Yes: ;NIH/NCI grant R01CA155446 DOD/PCRP grant W81XWH-12-1-0198.

60 APPLIED LIFE SCIENCES↗

WE-H-206-01: Photoacoustic Tomography: Multiscale Imaging From Organelles to Patients by Ultrasonically Beating the Optical Diffusion Limit

Lihong V. Wang: Photoacoustic tomography (PAT), combining non-ionizing optical and ultrasonic waves via the photoacoustic effect, provides in vivo multiscale functional, metabolic, and molecular imaging. Broad applications include imaging of the breast, brain, skin, esophagus, colon, vascular system, and lymphatic system in humans or animals. Light offers rich contrast but does not penetrate biological tissue in straight paths as x-rays do. Consequently, high-resolution pure optical imaging (e.g., confocal microscopy, two-photon microscopy, and optical coherence tomography) is limited to penetration within the optical diffusion limit (∼1 mm in the skin). Ultrasonic imaging, on the contrary, provides fine spatial resolution but suffers from both poor contrast in early-stage tumors and strong speckle artifacts. In PAT, pulsed laser light penetrates tissue and generates a small but rapid temperature rise, which induces emission of ultrasonic waves due to thermoelastic expansion. The ultrasonic waves, orders of magnitude less scattering than optical waves, are then detected to form high-resolution images of optical absorption at depths up to 7 cm, conquering the optical diffusion limit. PAT is the only modality capable of imaging across the length scales of organelles, cells, tissues, and organs (up to whole-body small animals) with consistent contrast. This rapidly growing technology promises to enable multiscale biological research and accelerate translation from microscopic laboratory discoveries to macroscopic clinical practice. PAT may also hold the key to label-free early detection of cancer by in vivo quantification of hypermetabolism, the quintessential hallmark of malignancy. Learning Objectives: To understand the contrast mechanism of PAT To understand the multiscale applications of PAT Benjamin M. W. Tsui: Multi-modality molecular imaging instrumentation and techniques have been major developments in small animal imaging that has contributed significantly to biomedical research during the past decade. The initial development was an extension of clinical PET/CT and SPECT/CT from human to small animals and combine the unique functional information obtained from PET and SPECT with anatomical information provided by the CT in registered multi-modality images. The requirements to image a mouse whose size is an order of magnitude smaller than that of a human have spurred advances in new radiation detector technologies, novel imaging system designs and special image reconstruction and processing techniques. Examples are new detector materials and designs with high intrinsic resolution, multi-pinhole (MPH) collimator design for much improved resolution and detection efficiency compared to the conventional collimator designs in SPECT, 3D high-resolution and artifact-free MPH and sparse-view image reconstruction techniques, and iterative image reconstruction methods with system response modeling for resolution recovery and image noise reduction for much improved image quality. The spatial resolution of PET and SPECT has improved from ∼6–12 mm to ∼1 mm a few years ago to sub-millimeter today. A recent commercial small animal SPECT system has achieved a resolution of ∼0.25 mm which surpasses that of a state-of-art PET system whose resolution is limited by the positron range. More recently, multimodality SA PET/MRI and SPECT/MRI systems have been developed in research laboratories. Also, multi-modality SA imaging systems that include other imaging modalities such as optical and ultrasound are being actively pursued. In this presentation, we will provide a review of the development, recent advances and future outlook of multi-modality molecular imaging of small animals. Learning Objectives: To learn about the two major multi-modality molecular imaging techniques of small animals. To learn about the spatial resolution achievable by the molecular imaging systems for small animal today. To learn about the new multi-modality imaging instrumentation and techniques that are being developed. Sang Hyun Cho; X-ray fluorescence (XRF) imaging, such as x-ray fluorescence computed tomography (XFCT), offers unique capabilities for accurate identification and quantification of metals within the imaging objects. As a result, it has emerged as a promising quantitative imaging modality in recent years, especially in conjunction with metal-based imaging probes. This talk will familiarize the audience with the basic principles of XRF/XFCT imaging. It will also cover the latest development of benchtop XFCT technology. Additionally, the use of metallic nanoparticles such as gold nanoparticles, in conjunction with benchtop XFCT, will be discussed within the context of preclinical multimodal multiplexed molecular imaging. Learning Objectives: To learn the basic principles of XRF/XFCT imaging To learn the latest advances in benchtop XFCT development for preclinical imaging Funding support received from NIH and DOD; Funding support received from GE Healthcare; Funding support received from Siemens AX; Patent royalties received from GE Healthcare; L. Wang, Funding Support: NIH; COI: Microphotoacoustics; S. Cho, Yes: ;NIH/NCI grant R01CA155446 DOD/PCRP grant W81XWH-12-1-0198.

60 APPLIED LIFE SCIENCES↗

WE-H-206-02: Recent Advances in Multi-Modality Molecular Imaging of Small Animals

Lihong V. Wang: Photoacoustic tomography (PAT), combining non-ionizing optical and ultrasonic waves via the photoacoustic effect, provides in vivo multiscale functional, metabolic, and molecular imaging. Broad applications include imaging of the breast, brain, skin, esophagus, colon, vascular system, and lymphatic system in humans or animals. Light offers rich contrast but does not penetrate biological tissue in straight paths as x-rays do. Consequently, high-resolution pure optical imaging (e.g., confocal microscopy, two-photon microscopy, and optical coherence tomography) is limited to penetration within the optical diffusion limit (∼1 mm in the skin). Ultrasonic imaging, on the contrary, provides fine spatial resolution but suffers from both poor contrast in early-stage tumors and strong speckle artifacts. In PAT, pulsed laser light penetrates tissue and generates a small but rapid temperature rise, which induces emission of ultrasonic waves due to thermoelastic expansion. The ultrasonic waves, orders of magnitude less scattering than optical waves, are then detected to form high-resolution images of optical absorption at depths up to 7 cm, conquering the optical diffusion limit. PAT is the only modality capable of imaging across the length scales of organelles, cells, tissues, and organs (up to whole-body small animals) with consistent contrast. This rapidly growing technology promises to enable multiscale biological research and accelerate translation from microscopic laboratory discoveries to macroscopic clinical practice. PAT may also hold the key to label-free early detection of cancer by in vivo quantification of hypermetabolism, the quintessential hallmark of malignancy. Learning Objectives: To understand the contrast mechanism of PAT To understand the multiscale applications of PAT Benjamin M. W. Tsui: Multi-modality molecular imaging instrumentation and techniques have been major developments in small animal imaging that has contributed significantly to biomedical research during the past decade. The initial development was an extension of clinical PET/CT and SPECT/CT from human to small animals and combine the unique functional information obtained from PET and SPECT with anatomical information provided by the CT in registered multi-modality images. The requirements to image a mouse whose size is an order of magnitude smaller than that of a human have spurred advances in new radiation detector technologies, novel imaging system designs and special image reconstruction and processing techniques. Examples are new detector materials and designs with high intrinsic resolution, multi-pinhole (MPH) collimator design for much improved resolution and detection efficiency compared to the conventional collimator designs in SPECT, 3D high-resolution and artifact-free MPH and sparse-view image reconstruction techniques, and iterative image reconstruction methods with system response modeling for resolution recovery and image noise reduction for much improved image quality. The spatial resolution of PET and SPECT has improved from ∼6–12 mm to ∼1 mm a few years ago to sub-millimeter today. A recent commercial small animal SPECT system has achieved a resolution of ∼0.25 mm which surpasses that of a state-of-art PET system whose resolution is limited by the positron range. More recently, multimodality SA PET/MRI and SPECT/MRI systems have been developed in research laboratories. Also, multi-modality SA imaging systems that include other imaging modalities such as optical and ultrasound are being actively pursued. In this presentation, we will provide a review of the development, recent advances and future outlook of multi-modality molecular imaging of small animals. Learning Objectives: To learn about the two major multi-modality molecular imaging techniques of small animals. To learn about the spatial resolution achievable by the molecular imaging systems for small animal today. To learn about the new multi-modality imaging instrumentation and techniques that are being developed. Sang Hyun Cho; X-ray fluorescence (XRF) imaging, such as x-ray fluorescence computed tomography (XFCT), offers unique capabilities for accurate identification and quantification of metals within the imaging objects. As a result, it has emerged as a promising quantitative imaging modality in recent years, especially in conjunction with metal-based imaging probes. This talk will familiarize the audience with the basic principles of XRF/XFCT imaging. It will also cover the latest development of benchtop XFCT technology. Additionally, the use of metallic nanoparticles such as gold nanoparticles, in conjunction with benchtop XFCT, will be discussed within the context of preclinical multimodal multiplexed molecular imaging. Learning Objectives: To learn the basic principles of XRF/XFCT imaging To learn the latest advances in benchtop XFCT development for preclinical imaging Funding support received from NIH and DOD; Funding support received from GE Healthcare; Funding support received from Siemens AX; Patent royalties received from GE Healthcare; L. Wang, Funding Support: NIH; COI: Microphotoacoustics; S. Cho, Yes: ;NIH/NCI grant R01CA155446 DOD/PCRP grant W81XWH-12-1-0198.

60 APPLIED LIFE SCIENCES↗

WE-H-206-03: Promises and Challenges of Benchtop X-Ray Fluorescence CT (XFCT) for Quantitative in Vivo Imaging

Lihong V. Wang: Photoacoustic tomography (PAT), combining non-ionizing optical and ultrasonic waves via the photoacoustic effect, provides in vivo multiscale functional, metabolic, and molecular imaging. Broad applications include imaging of the breast, brain, skin, esophagus, colon, vascular system, and lymphatic system in humans or animals. Light offers rich contrast but does not penetrate biological tissue in straight paths as x-rays do. Consequently, high-resolution pure optical imaging (e.g., confocal microscopy, two-photon microscopy, and optical coherence tomography) is limited to penetration within the optical diffusion limit (∼1 mm in the skin). Ultrasonic imaging, on the contrary, provides fine spatial resolution but suffers from both poor contrast in early-stage tumors and strong speckle artifacts. In PAT, pulsed laser light penetrates tissue and generates a small but rapid temperature rise, which induces emission of ultrasonic waves due to thermoelastic expansion. The ultrasonic waves, orders of magnitude less scattering than optical waves, are then detected to form high-resolution images of optical absorption at depths up to 7 cm, conquering the optical diffusion limit. PAT is the only modality capable of imaging across the length scales of organelles, cells, tissues, and organs (up to whole-body small animals) with consistent contrast. This rapidly growing technology promises to enable multiscale biological research and accelerate translation from microscopic laboratory discoveries to macroscopic clinical practice. PAT may also hold the key to label-free early detection of cancer by in vivo quantification of hypermetabolism, the quintessential hallmark of malignancy. Learning Objectives: To understand the contrast mechanism of PAT To understand the multiscale applications of PAT Benjamin M. W. Tsui: Multi-modality molecular imaging instrumentation and techniques have been major developments in small animal imaging that has contributed significantly to biomedical research during the past decade. The initial development was an extension of clinical PET/CT and SPECT/CT from human to small animals and combine the unique functional information obtained from PET and SPECT with anatomical information provided by the CT in registered multi-modality images. The requirements to image a mouse whose size is an order of magnitude smaller than that of a human have spurred advances in new radiation detector technologies, novel imaging system designs and special image reconstruction and processing techniques. Examples are new detector materials and designs with high intrinsic resolution, multi-pinhole (MPH) collimator design for much improved resolution and detection efficiency compared to the conventional collimator designs in SPECT, 3D high-resolution and artifact-free MPH and sparse-view image reconstruction techniques, and iterative image reconstruction methods with system response modeling for resolution recovery and image noise reduction for much improved image quality. The spatial resolution of PET and SPECT has improved from ∼6–12 mm to ∼1 mm a few years ago to sub-millimeter today. A recent commercial small animal SPECT system has achieved a resolution of ∼0.25 mm which surpasses that of a state-of-art PET system whose resolution is limited by the positron range. More recently, multimodality SA PET/MRI and SPECT/MRI systems have been developed in research laboratories. Also, multi-modality SA imaging systems that include other imaging modalities such as optical and ultrasound are being actively pursued. In this presentation, we will provide a review of the development, recent advances and future outlook of multi-modality molecular imaging of small animals. Learning Objectives: To learn about the two major multi-modality molecular imaging techniques of small animals. To learn about the spatial resolution achievable by the molecular imaging systems for small animal today. To learn about the new multi-modality imaging instrumentation and techniques that are being developed. Sang Hyun Cho; X-ray fluorescence (XRF) imaging, such as x-ray fluorescence computed tomography (XFCT), offers unique capabilities for accurate identification and quantification of metals within the imaging objects. As a result, it has emerged as a promising quantitative imaging modality in recent years, especially in conjunction with metal-based imaging probes. This talk will familiarize the audience with the basic principles of XRF/XFCT imaging. It will also cover the latest development of benchtop XFCT technology. Additionally, the use of metallic nanoparticles such as gold nanoparticles, in conjunction with benchtop XFCT, will be discussed within the context of preclinical multimodal multiplexed molecular imaging. Learning Objectives: To learn the basic principles of XRF/XFCT imaging To learn the latest advances in benchtop XFCT development for preclinical imaging Funding support received from NIH and DOD; Funding support received from GE Healthcare; Funding support received from Siemens AX; Patent royalties received from GE Healthcare; L. Wang, Funding Support: NIH; COI: Microphotoacoustics; S. Cho, Yes: ;NIH/NCI grant R01CA155446 DOD/PCRP grant W81XWH-12-1-0198.

60 APPLIED LIFE SCIENCES↗

A Collaboration and Commercialization Model for Exascale Software Research

In the US, recent software research and development for petascale systems has been performed by two main entities: US Government funded R&D collaborations (both at Universities and at Government Labs) and Industry efforts at products. With few notable exceptions, there has been little diffusion of technology from the R&D collaborations to industrial efforts and little feedback from the industrial efforts to the US government funded R&D efforts. However, the broader community has found value in some of the R&D efforts and would like to see continued support. For the most part, support is voluntary by the development groups because the funding was only for the R&D, not ongoing support. On the other hand, industry efforts end up being funded for specific platforms and are generally proprietary and suffer from the lack of overall effort due limited private and public investment. Understanding these lessons from petascale efforts is essential for forming a coherent strategy going forward to exascale. Clearly, a different research and development and commercialization model is desired going forward.

99 GENERAL AND MISCELLANEOUS↗

Global Oil & Gas Features Database

This submission contains a zip file with the developed Global Oil & Gas Features Database (as an ArcGIS geodatabase). Access the technical report describing how this database was produced using the following link: https://edx.netl.doe.gov/dataset/development-of-an-open-global-oil-and-gas-infrastructure-inventory-and-geodatabase This data can be viewed as a web map application at the following link: https://edx.netl.doe.gov/dataset/global-oil-gas-infrastructure-features-database-edx-spatial-webmap Acknowledgements: This work was performed under a CRADA between NETL and EDF, and was funded under the Climate and Clean Air Coalition (CCAC) Oil and Gas Methane Science Studies. The studies are managed by United Nations Environment in collaboration with the Office of the Chief Scientist, Steven Hamburg of the Environmental Defense Fund. Funding was provided by the Environmental Defense Fund, OGCI Companies (Shell, BP, ENI, Petrobras, Repsol, Total, Equinor, CNPC, Saudi Aramco, Exxon, Oxy, Chevron, Pemex) and CCAC.

Database↗

Development of an Open Global Oil and Gas Infrastructure Inventory and Geodatabase

This submission contains a technical report describing the development process and visual graphics for the Global Oil and Gas Infrastructure database. Access the GOGI database using the following link: https://edx.netl.doe.gov/dataset/global-oil-gas-features-database There is a web-mapping tool that allows you to visualize and interact with this data also available here: https://edxspatial.arcgis.netl.doe.gov/maps/edxspatial-gogi-index.html Acknowledgement: This work was performed under a CRADA between NETL and EDF, and was funded under the Climate and Clean Air Coalition (CCAC) Oil and Gas Methane Science Studies. The studies are managed by United Nations Environment in collaboration with the Office of the Chief Scientist, Steven Hamburg of the Environmental Defense Fund. Funding was provided by the Environmental Defense Fund, OGCI Companies (Shell, BP, ENI, Petrobras, Repsol, Total, Equinor, CNPC, Saudi Aramco, Exxon, Oxy, Chevron, Pemex) and CCAC.

GOGI↗

Global Oil & Gas Infrastructure Features Database EDX Spatial Web Map

This submission offers a link to a web mapping application hosted instance of the Global Oil & Gas Features Database (GOGI), via EDX Spatial. This offers users with the ability to visualize, interact, and create maps with data of their choice, as well as download specific attributes or fields of view from the database. This data can also be downloaded as a File Geodatabse from EDX at https://edx.netl.doe.gov/dataset/global-oil-gas-features-database. Access the technical report describing how this database was produced using the following link: https://edx.netl.doe.gov/dataset/development-of-an-open-global-oil-and-gas-infrastructure-inventory-and-geodatabase” This data was developed using a combination of big data computing, custom search and data integration algorithms, and expert driven search to collect open oil and gas data resources worldwide. This approach identified over 380 data sets and integrated more than 4.8 million features into the GOGI database. Acknowledgements: This work was funded under the Climate and Clean Air Coalition (CCAC) Oil and Gas Methane Science Studies. The studies are managed by United Nations Environment in collaboration with the Office of the Chief Scientist, Steven Hamburg of the Environmental Defense Fund. Funding was provided by the Environmental Defense Fund, OGCI Companies (Shell, BP, ENI, Petrobras, Repsol, Total, Equinor, CNPC, Saudi Aramco, Exxon, Oxy, Chevron, Pemex) and CCAC.

gas↗

Final Report for Phase I Northern California CO2 Reduction Project

On June 8, 2009, the U. S. Department of Energy's National Energy Technology Laboratory released a Funding Opportunity Announcement (DE-FOA 0000015) with the title, Recovery Act: Carbon Capture and Sequestration from Industrial Sources and Innovative Concepts for Beneficial CO{sub 2} Use. C6 Resources (C6), an affiliate of Shell Oil Company, responded with a proposal for Technology Area 1: Large-scale industrial carbon capture and sequestration (CCS) projects from industrial sources. As DOE Federally Funded Research and Development Center (FFRDC) Contractors, Lawrence Livermore National Laboratory (LBNL) and Lawrence Berkeley National Laboratory (LLNL) proposed to collaborate with C6 and perform technical tasks, which C6 included in the C6 proposal, titled the Northern California CO{sub 2} Reduction Project. The proposal was accepted for Phase I funding and C6 received DOE Award DEFE0002042. LLNL and LBNL each received Phase I funding of $200,000, directly from DOE. The essential task of Phase I was to prepare a proposal for Phase II, which would be a five-year, detailed technical proposal, budget, and schedule for a complete carbon capture, transportation, and geologic storage project, with the objective of starting the injection of 1 million tons per year of industrial CO2 by the end of FY2015. LLNL and LBNL developed technical proposals (and DOE Field Work Proposals [FWPs]) for many aspects of the geologic testing and CO{sub 2} monitoring that were included in the C6 Phase II proposal, which C6 submitted by the deadline of April 16, 2010. This document is the Final Report for LLNL's Phase I efforts and is presented in two parts. Part 1 is the complete text of the technical proposal provided to C6 by LLNL and LBNL for inclusion in the C6 Phase II proposal. Because of space limitations, however, C6 may not have included all of this information in their proposal. In addition to developing the proposal presented below, LLNL's Bill Foxall and Laura Chiarmonte, in collaboration with LBNL, undertook preliminary technical work evaluating the potential for induced seismicity in Solano County. Part 2 presents technical work preformed during Phase I in the development of a preliminary Certification Framework: Leakage Risk Assessment for CO{sub 2} Injection at the Montezuma Hills Site, Solano County, California, co-authored by LLNL and LBNL collaborators.

58 GEOSCIENCES↗

Solar 2 Green Energy, Arts & Education Center. Final Scientific/Technical Report

The Solar 2 Green Energy, Arts and Education Center is an 8,000 sq.ft. demonstration project that will be constructed to Platinum LEED certification and will be the first carbon-neutral, net-zero energy use public building in New York City, giving it local and national appeal. Employing green building features and holistic engineering practices throughout its international award-winning design, Solar 2 will be powered by a 90kW photovoltaic (PV) array in conjunction with a geothermal heating and cooling system and a high efficient design that seeks to reduce the overall energy load of the building. Solar 2 will replace our current 500 sq.ft. prototype facility - known as Solar 1 - as the educational and cultural centerpiece of a five-block public greenway on the East River in Stuyvesant Cove Park, located along two acres of public riverfront on a newly reclaimed, former brownfield in lower Manhattan. Designed as a public-use complex for year-round environmental education exhibits and onsite activities for all ages and backgrounds, Solar 2 will demonstrate energy-efficiency technologies and sustainable environmental practices available now to all urban residents, eco-tourists, teachers, and students alike. Showcasing one of Solar 2's most striking design elements is the PV roof array with a cafe and river vistas for miles of New York City's skylines. Capping the building as a solar-powered landmark, and visible from the FDR Drive, the PV array is also designed to provide visitors below a view of the solar roof when standing outside, as well as directly underneath it. Recognized by an international jury of architects, civil engineers and urban designers by the Swiss-based Holcim Foundation, the Solar 2 design was awarded the prestigious Holcim North American 2008 Gold Award for Sustainable Construction for innovative, future-oriented and tangible sustainable construction projects, selected from more than 1900 entries. Funding from the Department of Energy was provided to assist with the ongoing design work of Solar 2, including architecture, engineering and the development of construction specifications. The work performed during the project period brought this process as far along as it could go pending the raising of funds to begin construction of the building. Once those funds are secured, we will finalize any additional details needed before beginning the bidding process and then moving into construction. DOE's funding was extremely valuable in helping Solar One determine the feasibility of a net-zero construction on the site and allowed for the design to project to meet the high standards necessary for LEED Platinum status.

14 SOLAR ENERGY↗